<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40953879</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>14</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of an AI-enhanced management system for coronary heart disease (AIM-CHD): rationale and design of a single-centre, open-label, randomised, parallel-controlled trial.</ArticleTitle><Pagination><StartPage>e105597</StartPage><MedlinePgn>e105597</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e105597</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2025-105597</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Effective secondary prevention of coronary heart disease (CHD) is often hindered by limited healthcare resources and poor patient adherence. We therefore developed an artificial intelligence (AI)-enhanced CHD management platform (AIM-CHD) that (i) automatically captures follow-up data through AI-driven voice calls, optical character recognition of laboratory reports and wearable sensor streams; (ii) enables closed-loop, automated risk factor management; and (iii) dynamically personalises follow-up intensity via continuously updated risk stratification and achievement of treatment targets. This trial aims to evaluate whether AIM-CHD improves risk factor control and reduces cardiovascular events compared with usual care.</AbstractText><AbstractText Label="METHODS AND ANALYSIS" NlmCategory="METHODS">In this prospective, single-centre, open-label, randomised controlled trial, 1100 CHD patients aged 18-85 years will be enrolled at Fuwai Hospital and randomised 1:1 to either the AIM-CHD group (n=550) or the usual care group (n=550) for a 3&#x2009;month post-discharge intervention. The primary outcome is low-density lipoprotein cholesterol (LDL-C) level at 3 months. Secondary outcomes include target achievement for LDL-C and blood pressure, as well as glycosylated haemoglobin level, nonsmoking status, body mass index, composite cardiovascular endpoint and medication adherence.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION" NlmCategory="BACKGROUND">Ethical approval was approved by the Ethics Committee of Fuwai Hospital on 4 November 2024 (2024-2422). The findings will be disseminated in peer-reviewed publications. An anonymised template of the written informed-consent form (Chinese and English versions) is available as Supplementary Material 1.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">ClinicalTrial, NCT06686056.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Ba</LastName><ForeName>Zhengqing</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-0799-0337</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Beijing, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhao</LastName><ForeName>Sheng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Beijing, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Mengyuan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Beijing, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Guangzhi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Information Centre, Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Beijing, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lian</LastName><ForeName>Xiaodan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Information Centre, Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Beijing, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Information Centre, Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Beijing, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Yajing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Beijing, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zuoxiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Beijing, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Lanshu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Beijing, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ximei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Beijing, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Information Centre, Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Beijing, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Information Centre, Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Beijing, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Xiaojin</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-8158-484X</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Beijing, Beijing, China sophie_gao@sina.com zw@fuwai.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Information Centre, Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Beijing, Beijing, China sophie_gao@sina.com zw@fuwai.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yongjian</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0002-7803-0237</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Beijing, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT06686056</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003327" MajorTopicYN="Y">Coronary Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001185" MajorTopicYN="Y">Artificial Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="Y">Secondary Prevention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008078" MajorTopicYN="N">Cholesterol, LDL</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Artificial Intelligence</Keyword><Keyword MajorTopicYN="N">Coronary heart disease</Keyword><Keyword MajorTopicYN="N">Mobile Applications</Keyword><Keyword MajorTopicYN="N">Preventive Health Services</Keyword><Keyword MajorTopicYN="N">Randomized Controlled Trial</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>13</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>20</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40953879</ArticleId><ArticleId IdType="pmc">PMC12434780</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2025-105597</ArticleId><ArticleId IdType="pii">bmjopen-2025-105597</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>National Center for Cardiovascular Diseases, China Report on Cardiovascular Health and Diseases in China 2023: An Updated Summary. Chinese Circulation Journal. 2024;39:625&#x2013;59. doi: 10.3969/j.issn.1000-3614.2024.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1000-3614.2024.07.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720&#x2013;826. doi: 10.1093/eurheartj/ehad191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehad191</ArticleId><ArticleId IdType="pubmed">37622654</ArticleId></ArticleIdList></Reference><Reference><Citation>Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45:3415&#x2013;537. doi: 10.1093/eurheartj/ehae177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehae177</ArticleId><ArticleId IdType="pubmed">39210710</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Society of Cardiology (CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction] Zhonghua Xin Xue Guan Bing Za Zhi. 2019;47:766&#x2013;83. doi: 10.3760/cma.j.issn.0253-3758.2019.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.0253-3758.2019.10.003</ArticleId><ArticleId IdType="pubmed">31648459</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidelines for the management of non-ST elevation acute coronary syndromes (2024) Zhonghua Xin Xue Guan Bing Za Zhi. 2024;52:615&#x2013;46. doi: 10.3760/cma.j.cn112148-20240107-00014.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112148-20240107-00014</ArticleId><ArticleId IdType="pubmed">38880743</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese guidelines for the diagnosis and management of patients with chronic coronary syndrome. Zhonghua Xin Xue Guan Bing Za Zhi. 2024;52:589&#x2013;614. doi: 10.3760/cma.j.cn112148-20240325-00168.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112148-20240325-00168</ArticleId><ArticleId IdType="pubmed">38880742</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph P, Avezum &#xc1;, Ramasundarahettige C, et al. Secondary Prevention Medications in 17 Countries Grouped by Income Level (PURE): A Prospective Cohort Study. J Am Coll Cardiol. 2025;85:436&#x2013;47. doi: 10.1016/j.jacc.2024.10.121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2024.10.121</ArticleId><ArticleId IdType="pubmed">39909677</ArticleId></ArticleIdList></Reference><Reference><Citation>Spaulding EM, Marvel FA, Lee MA, et al. Corrie Health Digital Platform for Self-Management in Secondary Prevention After Acute Myocardial Infarction. Circ Cardiovasc Qual Outcomes. 2019;12:e005509. doi: 10.1161/CIRCOUTCOMES.119.005509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.119.005509</ArticleId><ArticleId IdType="pmc">PMC6697167</ArticleId><ArticleId IdType="pubmed">31043065</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley CK, Wang TY, Li S, et al. Patient-Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry. J Am Heart Assoc. 2019;8:e011765. doi: 10.1161/JAHA.118.011765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.118.011765</ArticleId><ArticleId IdType="pmc">PMC6509731</ArticleId><ArticleId IdType="pubmed">30913959</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, Zhang L, Lu Y, et al. Secondary prevention of cardiovascular disease in China. Heart. 2020;106:1349&#x2013;56. doi: 10.1136/heartjnl-2019-315884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2019-315884</ArticleId><ArticleId IdType="pubmed">31980439</ArticleId></ArticleIdList></Reference><Reference><Citation>Godinho MA, Jonnagaddala J, Gudi N, et al. mHealth for Integrated People-Centred Health Services in the Western Pacific: A Systematic Review. Int J Med Inform. 2020;142:104259. doi: 10.1016/j.ijmedinf.2020.104259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2020.104259</ArticleId><ArticleId IdType="pubmed">32858339</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi S, Chen S, Hong L, et al. Effect of Mobile Health Interventions on the Secondary Prevention of Cardiovascular Disease: Systematic Review and Meta-analysis. Can J Cardiol. 2017;33:219&#x2013;31. doi: 10.1016/j.cjca.2016.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2016.08.017</ArticleId><ArticleId IdType="pubmed">27956043</ArticleId></ArticleIdList></Reference><Reference><Citation>Marvel FA, Spaulding EM, Lee MA, et al. Digital Health Intervention in Acute Myocardial Infarction. Circ Cardiovasc Qual Outcomes. 2021;14:e007741. doi: 10.1161/CIRCOUTCOMES.121.007741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.121.007741</ArticleId><ArticleId IdType="pmc">PMC8288197</ArticleId><ArticleId IdType="pubmed">34261332</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow CK, Redfern J, Hillis GS, et al. Effect of Lifestyle-Focused Text Messaging on Risk Factor Modification in Patients With Coronary Heart Disease: A Randomized Clinical Trial. JAMA. 2015;314:1255&#x2013;63. doi: 10.1001/jama.2015.10945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.10945</ArticleId><ArticleId IdType="pubmed">26393848</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow CK, Klimis H, Thiagalingam A, et al. Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome: The TEXTMEDS Randomized Clinical Trial. Circulation. 2022;145:1443&#x2013;55. doi: 10.1161/CIRCULATIONAHA.121.056161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.056161</ArticleId><ArticleId IdType="pubmed">35533220</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Ge C, Shi Y, et al. Chinese Home-Based Cardiac Rehabilitation Model Delivered by Smartphone Interaction Improves Clinical Outcomes in Patients With Coronary Heart Disease. Front Cardiovasc Med. 2021;8:731557. doi: 10.3389/fcvm.2021.731557.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.731557</ArticleId><ArticleId IdType="pmc">PMC8523852</ArticleId><ArticleId IdType="pubmed">34676252</ArticleId></ArticleIdList></Reference><Reference><Citation>Scirica BM, Cannon CP, Fisher NDL, et al. Digital Care Transformation: Interim Report From the First 5000 Patients Enrolled in a Remote Algorithm-Based Cardiovascular Risk Management Program to Improve Lipid and Hypertension Control. Circulation. 2021;143:507&#x2013;9. doi: 10.1161/circulationaha.120.051913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.120.051913</ArticleId><ArticleId IdType="pmc">PMC8103500</ArticleId><ArticleId IdType="pubmed">33201729</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokuda L, Lorenzo L, Theriault A, et al. The utilization of video-conference shared medical appointments in rural diabetes care. Int J Med Inform. 2016;93:34&#x2013;41. doi: 10.1016/j.ijmedinf.2016.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2016.05.007</ArticleId><ArticleId IdType="pubmed">27435945</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood AJ, Cannon CP, Gordon WJ, et al. Results of a Remotely Delivered Hypertension and Lipid Program in More Than 10&#x202f;000 Patients Across a Diverse Health Care Network. JAMA Cardiol. 2023;8:12&#x2013;21. doi: 10.1001/jamacardio.2022.4018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2022.4018</ArticleId><ArticleId IdType="pmc">PMC9647559</ArticleId><ArticleId IdType="pubmed">36350612</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal S, LeFevre AE, Lee J, et al. Guidelines for reporting of health interventions using mobile phones: mobile health (mHealth) evidence reporting and assessment (mERA) checklist. BMJ. 2016;352:i1174. doi: 10.1136/bmj.i1174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i1174</ArticleId><ArticleId IdType="pubmed">26988021</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan A-W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013: new guidance for content of clinical trial protocols. Lancet. 2013;381:91&#x2013;2. doi: 10.1016/S0140-6736(12)62160-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)62160-6</ArticleId><ArticleId IdType="pubmed">23305999</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee WL, Danaee M, Abdullah A, et al. Is the Blood Pressure-Enabled Smartwatch Ready to Drive Precision Medicine? Supporting Findings From a Validation Study. Cardiol Res. 2023;14:437&#x2013;45. doi: 10.14740/cr1569.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/cr1569</ArticleId><ArticleId IdType="pmc">PMC10769613</ArticleId><ArticleId IdType="pubmed">38187511</ArticleId></ArticleIdList></Reference><Reference><Citation>Theurl F, Schreinlechner M, Sappler N, et al. Smartwatch-derived heart rate variability: a head-to-head comparison with the gold standard in cardiovascular disease. Eur Heart J Digit Health . 2023;4:155&#x2013;64. doi: 10.1093/ehjdh/ztad022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjdh/ztad022</ArticleId><ArticleId IdType="pmc">PMC10232241</ArticleId><ArticleId IdType="pubmed">37265873</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei L, He Z, Hu L. Accuracy of the Huawei GT2 Smartwatch for Measuring Physical Activity and Sleep Among Adults During Daily Life: Instrument Validation Study. JMIR Form Res . 2024;8:e59521. doi: 10.2196/59521.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/59521</ArticleId><ArticleId IdType="pmc">PMC11683742</ArticleId><ArticleId IdType="pubmed">39727144</ArticleId></ArticleIdList></Reference><Reference><Citation>Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291:2727&#x2013;33. doi: 10.1001/jama.291.22.2727.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.291.22.2727</ArticleId><ArticleId IdType="pubmed">15187054</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert J, Lindahl B, Melhus H, et al. Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. Eur Heart J. 2021;42:243&#x2013;52. doi: 10.1093/eurheartj/ehaa1011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa1011</ArticleId><ArticleId IdType="pmc">PMC7954251</ArticleId><ArticleId IdType="pubmed">33367526</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao Z, Bian X, Song C, et al. High stress hyperglycemia ratio predicts adverse clinical outcome in patients with coronary three-vessel disease: a large-scale cohort study. Cardiovasc Diabetol. 2024;23:190. doi: 10.1186/s12933-024-02286-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-024-02286-z</ArticleId><ArticleId IdType="pmc">PMC11144339</ArticleId><ArticleId IdType="pubmed">38824608</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Xu W, Song Q, et al. Association between the triglyceride-glucose index and severity of coronary artery disease. Cardiovasc Diabetol. 2022;21:168. doi: 10.1186/s12933-022-01606-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-022-01606-5</ArticleId><ArticleId IdType="pmc">PMC9438180</ArticleId><ArticleId IdType="pubmed">36050734</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Li G, Wang C, et al. Insulin resistance and coronary inflammation in patients with coronary artery disease: a cross-sectional study. Cardiovasc Diabetol. 2024;23:79. doi: 10.1186/s12933-024-02159-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-024-02159-5</ArticleId><ArticleId IdType="pmc">PMC10893710</ArticleId><ArticleId IdType="pubmed">38402392</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Zhao L, Lu Y, et al. Association between non-insulin-based insulin resistance indices and cardiovascular events in patients undergoing percutaneous coronary intervention: a retrospective study. Cardiovasc Diabetol. 2023;22:161. doi: 10.1186/s12933-023-01898-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-023-01898-1</ArticleId><ArticleId IdType="pmc">PMC10311786</ArticleId><ArticleId IdType="pubmed">37386494</ArticleId></ArticleIdList></Reference><Reference><Citation>China Gov  The seventh national population census 2021. 2021. https://www.gov.cn/xinwen/2021-05/12/content_5605913.htm Available.</Citation></Reference><Reference><Citation>Center Internet Network Information Center  The 54th statistical report on China&#x2019;s internet development 2024. 2024. https://www.cnnic.cn/n4/2024/0829/c88-11065.html Available.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>